Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLURISTEM THERAPEUTICS INC.

(PSTI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
2.93(c) 2.85(c) 2.96(c) 2.96(c) 3(c) Last
186 863 228 250 139 738 55 883 141 172 Volume
-1.68% -2.73% +3.86% 0.00% +1.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -56,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,79x
Yield 2022 -
Sales 2023 8,06 M - -
Net income 2023 -56,0 M - -
Net Debt 2023 - - -
P/E ratio 2023 -2,34x
Yield 2023 -
Capitalization 96,0 M 96,0 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 11,9x
Nbr of Employees -
Free-Float 87,4%
More Financials
Company
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell... 
More about the company
Ratings of Pluristem Therapeutics Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about PLURISTEM THERAPEUTICS INC.
09/13PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
09/13Pluristem Therapeutics Inc. Reports Earnings Results for the Full Year Ended ..
CI
07/19PLURISTEM THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K..
AQ
07/19PLURISTEM THERAPEUTICS : Appoints Prof. Varda Shalev MD and Mr. Doron Birger to ..
AQ
07/19Pluristem Therapeutics Inc. Appoints Varda Shalev and Doron Birger to Join it..
CI
07/08PLURISTEM THERAPEUTICS INC : Other Events (form 8-K)
AQ
07/08Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical R..
GL
07/08Pluristem Brings Acute Respiratory Distress Syndrome Associated with COVID-19..
CI
06/02PLURISTEM THERAPEUTICS : PSTI) Insider Makes Significant Share Sale
MT
06/02PLURISTEM THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders..
AQ
06/01INSIDER TRENDS : Pluristem Therapeutics Insider Extends 90-Day Selling Trend
MT
05/28PLURISTEM THERAPEUTICS : PSTI) Insider Makes Significant Share Sale
MT
05/27INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Pluristem Therapeutics
MT
05/25PLURISTEM THERAPEUTICS : Gets 20 Million Euros Investment Tranche From European ..
MT
05/25PLURISTEM THERAPEUTICS INC : Other Events (form 8-K)
AQ
More news
News in other languages on PLURISTEM THERAPEUTICS INC.

- No features available -

More news
Analyst Recommendations on PLURISTEM THERAPEUTICS INC.
More recommendations
Chart PLURISTEM THERAPEUTICS INC.
Duration : Period :
Pluristem Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLURISTEM THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,00 $
Average target price 8,63 $
Spread / Average Target 188%
EPS Revisions
Managers and Directors
Yaky Yanay President, Chief Executive Officer & Director
Chen Franco-Yehuda Chief Financial Officer, Secretary & Treasurer
Zami Aberman Executive Chairman
Racheli Ofir Vice President-Research & Intellectual Property
Nitsan Halevy Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PLURISTEM THERAPEUTICS INC.-57.57%96
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420